| Disease |
|
|
| CIN1/2/3 and CIS[@120538; @120553; @120554] |
|
406 |
| Cervical cancer, local disease[@120555] |
|
20 701 |
| Cervical cancer, regional disease[@120555] |
|
25 594 |
| Cervical cancer, distant disease[@120555] |
|
27 239 |
| VaIN1/2/3 and CIS[@120538; @120553] |
|
406 |
| Vaginal cancer, all stages[@120538] |
|
15 893 |
| Vulval cancer, all stages[@120538] |
|
15 893 |
| Penile cancer, all stages[@120556] |
10 482 |
|
| Anal cancer, all stages[@120557] |
18 292 |
|
| H&N cancer,a all stages[@120538] |
17 465 |
|
| Genital warts[@120558] |
292 |
|
| Recurrent respiratory papillomatosis[@120559] |
18 981 |
|
| Age-specific healthy state utilities |
|
|
| 1-17 |
0.93 |
0.93 |
| 18-34 |
0.92 |
0.91 |
| 35-44 |
0.90 |
0.89 |
| 45-54 |
0.87 |
0.86 |
| 55-64 |
0.81 |
0.80 |
| 65-74 |
0.76 |
0.78 |
| 75+ |
0.69 |
0.70 |
| HPV-related disease utilities |
|
|
| CIN1, VaIN1, VIN1 |
|
0.91 |
| CIN2+, CIS, VaIN2+, VIN2+ |
|
0.87 |
| Cervical/vaginal/vulvar/anal/H&Na/penile cancer, local |
0.76 |
|
| Cervical/vaginal/vulvar/anal/H&Na/penile cancer, regional |
0.67 |
|
| Cervical/vaginal/vulvar/anal/H&Na/penile cancer, distant |
0.48 |
|
| Cervical/vaginal/vulvar/anal/H&Na/penile cancer, survivor |
0.76 |
|
| Genital warts |
0.91 |
|
| RRP |
0.79 |
|